ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$939.68
30.18 (3.32%)
▲
5d:
+5.74%
30d:
+17.14%
90d:
+26.45%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
25d
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARGX shows positive signals but monitor for confirmation. Market pricing in 1.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ARGX shows positive signals but monitor for confirmation. Market pricing in 1.3% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1567.91
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$973.55
3.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $939.68, which is considered extended relative to its 30-day fair value range of $834.95 to $907.06. The stock's valuation (Forward PE: 29.2) is in line with its historical norms (28.1). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $953.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: ARGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1050.66 (+11.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $953.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: ARGX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $1050.66 (+11.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$834.95 -
$907.06
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading below Wall St target ($1050.66)
- NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$834.95 -
$907.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$837.74
Resistance Level
$953.58
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
29.18
Wall Street Target
$1050.66
(+11.8%)
Revenue Growth (YoY)
62.6%
Earnings Growth (YoY)
114.0%
Profit Margin
31.4%
Valuation Premium vs History
+1.3% premium
PE vs Historical
29.2 vs 28.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$951.90
(+1%)
2-Year Target
$964.27
(+3%)
3-Year Target
$976.81
(+4%)
3-Yr Target (if PE normalizes)
(PE: 29→28)
PE COMPRESSION
$940.74
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.2, Growth: 42.6%)
$2725.14
(+190%)
Base:
(SPY PE: 21.8, Growth: 42.6%)
$2034.24
(+117%)
Bear:
(PE: 18.5, Growth: 42.6%)
$1729.11
(+84%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 41.68 | Current EPS (TTM): $22.55
Bull Case
$1476.66
(+57%)
Analyst growth 42.8%, PE expands to 45.9
Base Case
$1342.42
(+43%)
Market implied 42.8%, PE stable at 41.7
Bear Case
$639.16
(-32%)
Severe decline -20.0%, PE contracts to 35.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 7:47 PM ET
Data refreshes hourly during market hours. Next update: 8:47 PM
Data refreshes hourly during market hours. Next update: 8:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
